Skip to main content
Fig. 5 | Human Genomics

Fig. 5

From: Enhancer promoter interactome and Mendelian randomization identify network of druggable vascular genes in coronary artery disease

Fig. 5

Functional impact of MAP3K11 inhibition on HCASMC. A–D VSMC treated with an inhibitor of MAP3K11 (URMC-099, 100 nM for 6 h) and expression mRNAs encoding for PLAU, CCL2, IL1B and EGR; n = 6. E Cell transmigration assay with URMC-099 (100 nM for 6 h); n = 6. The n represents experiments performed from 3 different donors in duplicate (performed at different passage); *P < 0.05

Back to article page

Human Genomics

ISSN: 1479-7364